Literature DB >> 28405326

Von Willebrand factor and alkaline phosphatase predict re-transplantation-free survival after the first liver transplantation.

Andreas Wannhoff1, Conrad Rauber1, Kilian Friedrich1, Christian Rupp1, Wolfgang Stremmel1, Karl Heinz Weiss1, Peter Schemmer2, Daniel N Gotthardt1.   

Abstract

BACKGROUND: After liver transplantation (LT), there are liver-related, infectious and cardiovascular complications that contribute to reduced graft survival. These conditions are associated with an increase in the Von Willebrand factor antigen (VWF-Ag), which was previously correlated with survival in cirrhotic patients.
OBJECTIVE: Evaluate VWF-Ag as a predictive marker of re-transplantation-free survival in patients after LT.
METHODS: We measured VWF-Ag in patients after first LT and then followed them prospectively with regard to the primary endpoint, namely re-transplantation-free survival.
RESULTS: There were 6 out of 80 patients who died or received re-LT during follow-up. In these patients, the median VWF-Ag was 510.6%, which was significantly higher (p = 0.001) than in the patients who were alive at the end of follow-up (with a median VWF-Ag = 186.8%). At a cut-off of 286.8%, VWF-Ag was significantly correlated with re-transplantation-free survival (p < 0.001). VWF-Ag was independently associated with re-transplantation-free survival in a multivariate analysis; as was alkaline phosphatase (ALP), but not the model of end-stage liver disease (MELD) score, donor age, nor cold ischemia time. A score combining VWF-Ag and ALP showed an impressive capability in the receiver operating characteristic (ROC) analysis (with area under the curve (AUC) = 0.958) to distinguish between patients with regard to the primary endpoint.
CONCLUSIONS: VWF-Ag is a non-invasive marker that can predict outcome in patients after LT. Its diagnostic performance increased when combined with ALP in a newly developed scoring system.

Entities:  

Keywords:  Alkaline phosphatase; Von Willebrand factor; diagnostic tests; liver transplantation; markers; outcome prediction; scoring system; survival; transplantation

Year:  2016        PMID: 28405326      PMCID: PMC5384554          DOI: 10.1177/2050640616650060

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  20 in total

1.  Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity.

Authors:  Ton Lisman; Tamara N Bongers; Jelle Adelmeijer; Harry L A Janssen; Moniek P M de Maat; Philip G de Groot; Frank W G Leebeek
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

2.  Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation.

Authors:  Michael R Lucey; Norah Terrault; Lolu Ojo; J Eileen Hay; James Neuberger; Emily Blumberg; Lewis W Teperman
Journal:  Liver Transpl       Date:  2013-01       Impact factor: 5.799

3.  Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis.

Authors:  C Rupp; A Rössler; E Halibasic; P Sauer; K-H Weiss; K Friedrich; A Wannhoff; A Stiehl; W Stremmel; M Trauner; D N Gotthardt
Journal:  Aliment Pharmacol Ther       Date:  2014-10-14       Impact factor: 8.171

4.  High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia.

Authors:  D Ferro; C Quintarelli; A Lattuada; R Leo; M Alessandroni; P M Mannucci; F Violi
Journal:  Hepatology       Date:  1996-06       Impact factor: 17.425

5.  D-MELD, a simple predictor of post liver transplant mortality for optimization of donor/recipient matching.

Authors:  J B Halldorson; R Bakthavatsalam; O Fix; J D Reyes; J D Perkins
Journal:  Am J Transplant       Date:  2008-12-15       Impact factor: 8.086

6.  Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.

Authors:  Christophe Corpechot; Ludovico Abenavoli; Nabila Rabahi; Yves Chrétien; Tony Andréani; Catherine Johanet; Olivier Chazouillères; Raoul Poupon
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

7.  Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C.

Authors:  A Maieron; P Salzl; M Peck-Radosavljevic; M Trauner; S Hametner; R Schöfl; P Ferenci; M Ferlitsch
Journal:  Aliment Pharmacol Ther       Date:  2013-12-05       Impact factor: 8.171

8.  Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  Said Al Mamari; Jelena Djordjevic; John S Halliday; Roger W Chapman
Journal:  J Hepatol       Date:  2012-10-22       Impact factor: 25.083

9.  OPTN/SRTR 2012 Annual Data Report: liver.

Authors:  W R Kim; J M Smith; M A Skeans; D P Schladt; M A Schnitzler; E B Edwards; A M Harper; J L Wainright; J J Snyder; A K Israni; B L Kasiske
Journal:  Am J Transplant       Date:  2014-01       Impact factor: 8.086

10.  Effects of increased von Willebrand factor levels on primary hemostasis in thrombocytopenic patients with liver cirrhosis.

Authors:  Andreas Wannhoff; Oliver J Müller; Kilian Friedrich; Christian Rupp; Petra Klöters-Plachky; Yvonne Leopold; Maik Brune; Mirja Senner; Karl-Heinz Weiss; Wolfgang Stremmel; Peter Schemmer; Hugo A Katus; Daniel N Gotthardt
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

View more
  2 in total

1.  Novel Non-Histocompatibility Antigen Mismatched Variants Improve the Ability to Predict Antibody-Mediated Rejection Risk in Kidney Transplant.

Authors:  Silvia Pineda; Tara K Sigdel; Jieming Chen; Annette M Jackson; Marina Sirota; Minnie M Sarwal
Journal:  Front Immunol       Date:  2017-12-05       Impact factor: 7.561

2.  Assessment of hemostatic profile in patients with mild to advanced liver cirrhosis.

Authors:  Elisabeth Hannah Adam; Madara Möhlmann; Eva Herrmann; Sonia Schneider; Kai Zacharowski; Stefan Zeuzem; Christian Friedrich Weber; Nina Weiler
Journal:  World J Gastroenterol       Date:  2020-05-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.